Literature DB >> 11568071

Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment.

G Sangiorgi1, R D'Averio, A Mauriello, M Bondio, M Pontillo, S Castelvecchio, S Trimarchi, V Tolva, G Nano, V Rampoldi, L G Spagnoli, L Inglese.   

Abstract

BACKGROUND: Structural alterations of aortic wall resulting from degradation of matrix proteins by matrix metalloproteinases (MMPs) characterize abdominal aortic aneurysms (AAAs). No studies have compared circulating levels of MMPs after endovascular graft (EVG) exclusion in comparison with open surgical repair (OSR) in patients affected by AAA. METHODS AND
RESULTS: An abdominal angiography and CT scan were performed in all patients at the time of enrollment. A spiral CT scan was performed at 6 months to detect presence of endoleaks. MMP-3 and MMP-9 levels were measured before EVG (n=30) and OSR (n=15) treatments and at 1, 3, and 6 months of follow-up by a sandwich ELISA technique. Healthy volunteers (n=10) were used as control subjects. Immunohistochemical staining for MMP-9 and MMP-3 was performed on tissue samples from surgical cases. Both MMP-9 and MMP-3 mean basal levels were significantly higher in patients affected by AAA than in control subjects (32.3+/-20.7 ng/mL for EVG and 28+/-9.9 ng/mL for OSR versus 8.9+/-2.5 ng/mL, 2P<0.05; 18.3+/-9.7 ng/mL and 26.7+/-10.8 ng/mL versus 8.2+/-5.3 ng/mL, 2P<0.001). In the OSR group, both MMP-9 and MMP-3 mean levels decreased after surgery (28+/-9.9 ng/mL at basal versus 14.7+/-6.6 ng/mL at 6 months, 2P<0.001; 26.7+/-10.8 versus 12+/-5.3 ng/mL; 2P<0.001). In the EVG group, a statistically significant difference at 6-month follow-up in MMP-9 and MMP-3 mean plasma values was detected in patients who had endoleakage in comparison with patients without endoleakage (44.3+/-20.7 versus 14.6+/-7.0 ng/mL, 2P<0.005; 25+/-11.5 versus 10.3+/-5.4 ng/mL, 2P<0.005).
CONCLUSIONS: After EVG exclusion, MMP-9 and MMP-3 levels decreased to a level similar to that of patients undergoing OSR. In addition, a lack of decrease in MMP levels after EVG exclusion may help in identifying patients who will have endoleakage and consequent aneurysm expansion caused by continuous sac pressurization during follow-up.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568071     DOI: 10.1161/hc37t1.094596

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

Review 1.  Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch.

Authors:  Tom P Theruvath; Jeffrey A Jones; John S Ikonomidis
Journal:  J Card Surg       Date:  2011-09-29       Impact factor: 1.620

Review 2.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 3.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 4.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 5.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

Review 6.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

7.  Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms.

Authors:  Vincent Fontaine; Marie-Paule Jacob; Xavier Houard; Patrick Rossignol; Didier Plissonnier; Eduardo Angles-Cano; Jean-Baptiste Michel
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 8.  Circulating markers of abdominal aortic aneurysm presence and progression.

Authors:  Jonathan Golledge; Philip S Tsao; Ronald L Dalman; Paul E Norman
Journal:  Circulation       Date:  2008-12-02       Impact factor: 29.690

Review 9.  Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm.

Authors:  Faisal Aziz; Helena Kuivaniemi
Journal:  Ann Vasc Surg       Date:  2007-05       Impact factor: 1.466

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.